Learn about hypertrophic cardiomyopathy, the leading cause of sudden cardiac death in young athletes. Understand the symptoms ...

Mavacamten treatment at 48 weeks was not associated with significant improvements in patient-reported health status or peak ...

Aficamten treatment was associated with significant improvements in exercise capacity and symptoms compared with metoprolol ...

In one of two trials that substantially expand clinical evidence with myosin inhibitors in the treatment of hypertrophic cardiomyopathy (HCM), a next-in-class agent beat beta-blockers in first-line ...

Mavacamten treatment at 48 weeks was not associated with significant improvements in patient-reported health status or peak oxygen consumption compared with placebo in patients with symptomatic ...

Beta-blockers are commonly used in the initial treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM), despite limited evidence of their efficacy.  The MAPLE-HCM trial compared the ...